Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
作者信息
Pea Federico, Cojutti Piergiorgio, Petrosillo Nicola, Furlanut Mario, Entenza J M, Veloso T R, Vouillamoz J, Giddey M, Moreillon P
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4496; author reply 4496-7. doi: 10.1128/AAC.00603-11.
Abstract
摘要
相似文献
1
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.持续输注可能会提高万古霉素治疗由异质性万古霉素中介金黄色葡萄球菌引起的实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2011 Sep;55(9):4496; author reply 4496-7. doi: 10.1128/AAC.00603-11.
2
Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.万古霉素持续输注治疗耐万古霉素中间葡萄球菌所致实验性心内膜炎失败。
Antimicrob Agents Chemother. 2011 Jan;55(1):385-7. doi: 10.1128/AAC.00811-10. Epub 2010 Oct 18.
3
Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.替拉万星成功治疗耐万古霉素中间型金黄色葡萄球菌起搏器导线感染性心内膜炎。
Antimicrob Agents Chemother. 2010 Dec;54(12):5376-8. doi: 10.1128/AAC.00857-10. Epub 2010 Sep 27.
4
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.系统评价和荟萃分析异质性万古霉素中介金黄色葡萄球菌分离株的意义。
Antimicrob Agents Chemother. 2011 Jan;55(1):405-10. doi: 10.1128/AAC.01133-10. Epub 2010 Nov 15.
5
In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.头孢洛林与万古霉素治疗耐万古霉素中间葡萄球菌实验性心内膜炎的体内协同作用。
Antimicrob Agents Chemother. 2011 Sep;55(9):3977-84. doi: 10.1128/AAC.00402-11. Epub 2011 Jul 5.
6
Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.台湾地区一株对达托霉素不敏感、对万古霉素中介且耐甲氧西林的金黄色葡萄球菌引起的菌血症和感染性心内膜炎
J Clin Microbiol. 2008 Mar;46(3):1132-6. doi: 10.1128/JCM.01844-07. Epub 2008 Jan 16.
7
Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.由对万古霉素敏感性降低的金黄色葡萄球菌引起的感染性心内膜炎。
Clin Infect Dis. 2004 Apr 15;38(8):1188-91. doi: 10.1086/383027. Epub 2004 Apr 5.
8
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.在兔心内膜炎模型中，新型广谱头孢菌素头孢洛林（PPI-0903）与利奈唑胺和万古霉素相比，对耐甲氧西林和万古霉素中介金黄色葡萄球菌的体内疗效。
Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25.
9
Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.万古霉素中介金黄色葡萄球菌（VISA）和异质性万古霉素中介金黄色葡萄球菌（hVISA）中的达托霉素不敏感性：万古霉素治疗失败后治疗的影响。
J Antimicrob Chemother. 2011 May;66(5):1057-60. doi: 10.1093/jac/dkr066. Epub 2011 Mar 2.
10
Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.替考拉宁在耐甲氧西林金黄色葡萄球菌或万古霉素中介金黄色葡萄球菌所致兔主动脉瓣心内膜炎模型中的疗效
Antimicrob Agents Chemother. 2005 Aug;49(8):3163-5. doi: 10.1128/AAC.49.8.3163-3165.2005.
引用本文的文献
1
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?抗生素药代动力学30年回顾：是时候开展药物遗传学研究了吗？
Curr Drug Metab. 2014;15(6):581-98. doi: 10.2174/1389200215666140605130935.
本文引用的文献
1
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.系统评价和荟萃分析异质性万古霉素中介金黄色葡萄球菌分离株的意义。
Antimicrob Agents Chemother. 2011 Jan;55(1):405-10. doi: 10.1128/AAC.01133-10. Epub 2010 Nov 15.
2
Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.万古霉素持续输注治疗耐万古霉素中间葡萄球菌所致实验性心内膜炎失败。
Antimicrob Agents Chemother. 2011 Jan;55(1):385-7. doi: 10.1128/AAC.00811-10. Epub 2010 Oct 18.
3
Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.达托霉素、利奈唑胺和替加环素对嵌入生物膜的导管相关耐甲氧西林金黄色葡萄球菌血症分离株的比较活性。
Antimicrob Agents Chemother. 2007 May;51(5):1656-60. doi: 10.1128/AAC.00350-06. Epub 2007 Mar 12.
4
Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.长期使用万古霉素对一名复发性菌血症患者体内耐甲氧西林金黄色葡萄球菌（MRSA）的影响。
J Antimicrob Chemother. 2006 Apr;57(4):699-704. doi: 10.1093/jac/dkl030. Epub 2006 Feb 7.
5
The pharmacokinetic and pharmacodynamic properties of vancomycin.万古霉素的药代动力学和药效学特性。
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. doi: 10.1086/491712.
6
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.莫西沙星、环丙沙星和万古霉素对表达不同程度环丙沙星耐药性的耐甲氧西林金黄色葡萄球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2001 Nov;45(11):3076-83. doi: 10.1128/AAC.45.11.3076-3083.2001.
7
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.左氧氟沙星与环丙沙星、氟氯西林或万古霉素治疗甲氧西林敏感或耐药金黄色葡萄球菌所致实验性心内膜炎的疗效比较
Antimicrob Agents Chemother. 1997 Aug;41(8):1662-7. doi: 10.1128/AAC.41.8.1662.
Zotero 插件